GeneOne Life Science: Losses Narrow but CDMO Revenue Void and Litigation Risks Persist
Consolidated operating loss of 2.34B won, net loss of 2.38B won, narrowing from same period last year (Q1 prior: operating loss 9.07B, net loss 8.84B)
Revenue plunged to 2.58B won from 8.5B won, mainly due to zero CDMO revenue (prior 5.57B)
Equity raised via rights issue (5.47M shares, ~8B won) and capital reduction decision; debt ratio improved from 191.5% to 156.6%
Large impairment losses recognized for subsidiary VGXI (approx. 138.6B won in loans and accrued income) and multiple ongoing lawsuits (including one final loss)
Drug pipeline (SFTS vaccine, GLS-1027, GLS-1200) seeking tech transfer, but commercialization timeline uncertain
No quarterly dividend or share buyback/cancellation (no shareholder return)